INTRODUCTION {#s1}
============

Diabetes mellitus (DM) is a growing global pandemic afflicting approximately three to four percent of adults worldwide. An estimated 366 million people worldwide will development in DM by 2030 \[[@R1]--[@R4]\]. DM may predispose patients to premature illness and death due to the relevant risk of cardiovascular diseases \[[@R5]--[@R6]\]. In addition, the relationship between DM and cancer risk has been examined in numerous meta-analyses \[[@R7]--[@R14]\]. Epidemiologic studies examining the association between DM and gastric cancer risk have largely been inconclusive and provide conflicting results \[[@R15]--[@R21]\], including two meta-analyses of the relationship between DM and the risk of gastric cancer \[[@R22]--[@R23]\]. Furthermore, whether these relationships differ according to gender in specific subpopulations remains controversial.

In 2012 alone, there were approximately 952,000 gastric cancer cases and 723,000 deaths from gastric cancer worldwide, accounting for 6.8% of the total cancer cases and 8.8% of all cancer deaths \[[@R24]\]. Several meta-analyses have indicated that numerous lifestyle factors might play beneficial or harmful impacts on the risk of gastric cancer \[[@R25]--[@R27]\]. Yang et al suggested that being overweight or obese associates with an increased risk of gastric cancer and the strength of this relationship increases with increasing body mass index (BMI) \[[@R28]\]. It is also worth noting that increased BMI is associated with an increased risk of DM \[[@R29]\]. Clarifying the potential role that DM plays on the risk of gastric cancer is particularly important in the DM populations, as it has not been definitively determined. Hence, the role of DM on the risk of gastric cancer incidence or mortality still needs further evaluation and discussion. Here we attempted a large-scale examination of the available cohort studies to determine the association between DM and the incidence of gastric cancer or gastric cancer mortality. Furthermore, we also evaluated gender differences in this relationship in patients with different baseline characteristics.

RESULTS {#s2}
=======

Literature search {#s2_1}
-----------------

The process of study selection is presented as a flow chart in Figure [1](#F1){ref-type="fig"}. A total of 2,130 articles from the initial search were identified and screened, of which 2096 were excluded due to being irrelevant, reviews, letters to the editor, having a case control design, producing no desirable outcomes, or including participants with other diseases. A total of 34 studies were reviewed in detail, and 4 without gastric cancer incidence or mortality outcomes were ruled out and another 8 studies were excluded as being different publications of the same sample of participants, thereby including main results that had already been reviewed \[[@R30]--[@R37]\]. Ultimately, 22 studies were eligible for the final pooled analysis \[[@R15]--[@R21], [@R49]--[@R63]\]. A manual search of the reference lists of these studies did not yield any new eligible studies. The general characteristics of the included studies are presented in Table [1](#T1){ref-type="table"}.

![Flow diagram of the literature search and trials selection process](oncotarget-08-44881-g001){#F1}

###### Baseline characteristics of studies included in the systematic review and meta-analysis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                            Place      Assessment of exposure                 Sample size   Age at baseline                   Gender (M/F)    Percentage of overweight (%)   Gastric cancer cases   Death due to gastric cancer cases   Effect estimate   Follow-up (year)                 Adjusted factors                                                                                                                                NOS score
  ------------------------------------------------ ---------- -------------------------------------- ------------- --------------------------------- --------------- ------------------------------ ---------------------- ----------------------------------- ----------------- -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Wideroff L 1997 \[[@R15]\]                       Denmark    Danish Cancer Registry                 109581        64.0 for men and 69.0 for women   54571/55010     NA                             319                    NA                                  SIR               17.0                             Age, sex, calendar year                                                                                                                         6

  CPS II 2004 \[[@R49]\]                           USA        Self administered questionnaire        1056243       57.0                              467922/588321   48.9                           NA                     109                                 RR                12.5                             Age, sex, race, education, family history, BMI, PA, smoking, alcohol, diet                                                                      8

  NHIC 2005 \[[@R16]\]                             Korea      Self-report and blood glucose levels   1298385       47.0                              829770/468615   NA                             1120                   511                                 HR                10.0                             Age, smoking, alcohol                                                                                                                           9

  JPHC 2006 \[[@R50]\]                             Japan      Self-report                            97771         51.4 for men and 51.8 for women   46548/51223     27.3                           1339                   NA                                  HR                14.0                             Age, study area, VD,\                                                                                                                           8
                                                                                                                                                                                                                                                                                                                  smoking, alcohol, BMI, PA, vegetable and coffee intake                                                                                          

  MHS 2010 \[[@R51]\]                              Israel     Self-report or blood\                  100595        61.6                              52913/47682     79.4                           307                    NA                                  HR                8.0                              Age, region, SES level, use of healthcare services, BMI, and history of VD                                                                      7
                                                              glucose level                                                                                                                                                                                                                                                                                                                                                                                       

  Hemminki K 2010 \[[@R17]\]                       Sweden     Medical records                        125126        \>39.0                            NA              NA                             469                    NA                                  SIR               15.0                             NA                                                                                                                                              5

  NIH-AARP Diet and Health Study 2011 \[[@R18]\]   USA        Self-report                            469448        62.0                              280883/188565   64.6                           631                    NA                                  HR                10.0                             Age, sex, calories, alcohol, smoking, fruit consumption, ethnicity, education, and PA                                                           8

  Tseng CH 2011 \[[@R52]\]                         Taiwan     Self-report                            88694         \>25.0                            40799/47895     NA                             NA                     1049                                SMR               12.0                             Age and sex                                                                                                                                     6

  Verona Diabetes\                                 Italy      Medical records                        7148          67.0                              3366/3782       70.7                           NA                     48                                  SMR               10.0                             Age, smoking, BMI                                                                                                                               7
  Study 2003 \[[@R53]\]                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Swerdlow AJ 2005 \[[@R54]\]                      UK         Self-report                            5066          30-49                             2944/2122       NA                             12                     9                                   SIR               18.0                             Age, sex, calendar year,\                                                                                                                       6
                                                                                                                                                                                                                                                                                                                  residence                                                                                                                                       

  Kessler II 1970 \[[@R55]\]                       USA        Blood glucose test                     218313        40-59                             96010/122313    NA                             NA                     98                                  SMR               10.0                             Age, sex                                                                                                                                        6

  HIC 2009 \[[@R56]\]                              Scotland   Self-report                            28731         62.0                              15227/13504     NA                             NA                     62                                  RR                3.9                              Deprivation decile                                                                                                                              7

  U.S. Veterans 2010 \[[@R57]\]                    USA        Discharge diagnosis                    4501578       59.1                              4501578/0       5.7                            7515                   NA                                  RR                10.5                             Age, time, latency, race, number of visits,alcohol, obesity and COPD                                                                            8

  Zendehdel K 2003 \[[@R19]\]                      Sweden     Medical records                        29187         38.7                              14864/14323     NA                             10                     NA                                  SIR               14.4                             Excluding the 1 st -year of follow-up                                                                                                           7

  Koskinen SV 1998 \[[@R58]\]                      Finland    Census records                         58000         30-74                             24000/34000     NA                             NA                     73                                  RR                5.0                              Age                                                                                                                                             6

  JACC 2006 \[[@R20]\]                             Japan      Self administered\                     56881         40-79                             23378/33503     19.8                           631                    NA                                  RR                18.0-20.0                        Age, BMI, smoking, and drinking                                                                                                                 8
                                                              questionnaire                                                                                                                                                                                                                                                                                                                                                                                       

  Ragozzino M 1982 \[[@R59]\]                      USA        Blood glucose levels                   1135          61.0                              602/533         NA                             8                      NA                                  SIR               8.6                              Age, sex                                                                                                                                        7

  Adami HO 1991 \[[@R21]\]                         Sweden     Medical records                        51008         NA                                23146/27862     NA                             159                    NA                                  RR                5.2                              Age, sex                                                                                                                                        6

  Whitehall study 2004 \[[@R60]\]                  UK         Oral glucose tolerance test            18006         51.5                              18006/0         NA                             NA                     162                                 HR                25.0                             Age, employment, smoking, SBP, PA, disease history                                                                                              7

  NHIRD 2013 \[[@R61]\]                            Taiwan     Medical records                        98125         56.0                              54675/43450     NA                             263                    NA                                  HR                5.5                              Age, sex, CGD, pneumoconiosis                                                                                                                   8

  Strong Heart Study 2015 \[[@R62]\]               USA        Self administered\                     4419          55.1                              1794/2625       50.9                           NA                     19                                  HR                20.0                             Age, sex, center, BMI, education, drinking status and smoking                                                                                   8
                                                              questionnaire                                                                                                                                                                                                                                                                                                                                                                                       

  Xu HL 2015 \[[@R63]\]                            China      Self administered\                     136421        53.4                              61480/74941     NA                             755                    NA                                  HR                7.5 for men and 13.2 for women   Age, sex, education, income, BMI, CGD, family history of stomach cancer, PA, EI, smoking, tea, alcohol, vegetable, red meat, and fruit intake   8
                                                              questionnaire                                                                                                                                                                                                                                                                                                                                                                                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BMI: body mass index; PA: physical activity; VD: vascular disease; EI: energy intake; CGD: chronic gastric disease; NA: not available.

Study characteristics {#s2_2}
---------------------

The 22 included studies covered a total of 8,559,861 individuals and reported 13,538 new gastric cancer cases and 2,140 deaths due to gastric cancer. The sample size for each individual study was 1,135-4,501,578 participants, while the follow-up period for participants was 3.9-25.0 years. Seven studies were conducted in Asia \[[@R16],[@R20], [@R50]--[@R52], [@R61], [@R63]\], 9 in Europe \[[@R15], [@R17], [@R19], [@R21], [@R53], [@R54], [@R56], [@R58], [@R60]\], and 6 in the USA \[[@R18], [@R49], [@R55], [@R57], [@R59], [@R62]\]. 4 studies used self-administered questionnaires \[[@R20], [@R49], [@R62], [@R63]\], 7 studies used self-reporting \[[@R16], [@R18], [@R50]--[@R52], [@R54], [@R56]\], 7 studies used medical records \[[@R15], [@R17], [@R19], [@R21], [@R53], [@R58], [@R61]\], and the remaining 4 studies used blood glucose tests \[[@R55], [@R57], [@R59], [@R60]\] to assess exposure. Eight studies used SIR/SMR to evaluate the relationship between DM and gastric cancer incidence or mortality \[[@R15],[@R1] [@R7], [@R19], [@R52]--[@R55], [@R59]\], and the remaining 14 studies used OR, RR or HR to calculate this association \[[@R16], [@R18], [@R20], [@R21], [@R49]-[@R51], [@R56]-[@R58], [@R60]-[@R63]\]. Fourteen studies evaluated the relationship between DM and the incidence of gastric cancer \[[@R15]-[@R21], [@R50], [@R51], [@R54], [@R57], [@R59], [@R61], [@R63]\], and ten studies evaluated the relationship between DM and the risk of gastric cancer mortality \[[@R16], [@R49], [@R52]-[@R56], [@R58], [@R60], [@R62]\]. Study quality was evaluated using the NOS score (Table [1](#T1){ref-type="table"}) \[[@R39]\]. Overall, 1 study had a score of 9 \[[@R16]\], 8 studies had a score of 8 \[[@R18], [@R20], [@R49], [@R50], [@R57], [@R61]-[@R63]\], 6 studies had a score of 7 \[[@R19], [@R51], [@R53], [@R56], [@R59], [@R60]\], 6 studies had a score of 6 \[[@R15], [@R21], [@R52], [@R54], [@R55], [@R58]\], and the remaining 1 study had a score of 5 \[[@R17]\].

DM and the risk of gastric cancer incidence or mortality {#s2_3}
--------------------------------------------------------

A total of 15 studies reported an association between DM and the incidence of gastric cancer \[[@R15]-[@R21], [@R50], [@R51], [@R54], [@R56], [@R57], [@R59], [@R61], [@R63]\]. The summary RR showed that participants with DM were not associated with a change in gastric cancer risk (RR: 1.10; 95%CI: 0.94-1.29; *P* = 0.229; Figure [2A](#F2){ref-type="fig"}), but substantial heterogeneity was detected (*P* \< 0.001). Furthermore, a total of 9 studies reported an association between DM and the risk of gastric cancer mortality \[[@R16], [@R49], [@R52]-[@R55], [@R58], [@R60], [@R62]\]. There was no significant association between DM patients and participants without DM for gastric cancer mortality across all studies (RR: 1.28; 95%CI: 0.93-1.76; *P* = 0.123; Figure [2B](#F2){ref-type="fig"}). Substantial heterogeneity was observed in the magnitude of the effect across the studies (*P* \< 0.001).

![Association of diabetes mellitus with the risk of gastric cancer incidence (**A**) and mortality (**B**).](oncotarget-08-44881-g002){#F2}

DM and the risk of gastric cancer incidence in men and women {#s2_4}
------------------------------------------------------------

There were 11 studies with data available for men \[[@R15], [@R16], [@R18], [@R20], [@R21], [@R50], [@R51], [@R57], [@R59], [@R61], [@R63]\] and 10 studies for women \[[@R15], [@R16], [@R18], [@R20], [@R21], [@R50], [@R51], [@R59], [@R61], [@R63]\]. The summary analysis results for men and women with or without DM showed that DM was not associated with the risk of gastric cancer incidence in men (RR: 1.00; 95%CI: 0.90-1.11; *P* = 0.972; Figure [3A](#F3){ref-type="fig"}) or in women (RR: 1.07; 95%CI: 0.93-1.22; *P* = 0.368; Figure [3B](#F3){ref-type="fig"}). Gender difference was not significantly associated with the relationship between DM and gastric cancer incidence (RRR: 0.93; 95%CI: 0.77-1.14; *P* = 0.495). Furthermore, we noted potential evidence of heterogeneity for gastric cancer in men (I-square: 67.0%; *P* = 0.001), and mild heterogeneity for gastric cancer in women (I-square: 35.1%; *P* = 0.127). Once sensitivity analyses were conducted for men and women, we noted that the conclusion was not affected by the systematic exclusion of any one specific study from the pool (Supplemental 2: [Tables S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}). However, women were found to have increased risk for gastric cancer when excluding the JACC study \[[@R20]\] (RR: 1.09; 95%CI: 0.99-1.20; P *P* = 0.066; I-square: 0.9%; *P* value for heterogeneity: 0.426), which illustrated the incidence of gastric cancer is gradually decreasing in Japan recently.

![Association of diabetes mellitus with the risk of gastric cancer incidence in men (**A**) and women (**B**).](oncotarget-08-44881-g003){#F3}

DM and the risk of gastric cancer mortality in men and women {#s2_5}
------------------------------------------------------------

The breakdown for the number of studies available for mortality associations with men and women was 6 \[[@R16], [@R49], [@R52], [@R53], [@R58], [@R60]\] and 5 studies \[[@R16], [@R49], [@R52], [@R53], [@R58]\], respectively. The summary analysis results for men and women with or without DM indicated that DM was not associated with the risk of gastric cancer mortality in men (RR: 1.33; 95%CI: 0.93-1.89; *P* = 0.114; Figure [4A](#F4){ref-type="fig"}) or women (RR: 1.40; 95%CI: 0.95-2.06; *P* = 0.085; Figure [4B](#F4){ref-type="fig"}). The RRR indicated that no gender difference existed for this relationship (RRR: 0.95; 95%CI: 0.56-1.61; *P* = 0.848). Substantial heterogeneity was detected for gastric cancer mortality in men and women (men: I-square: 96.0%, *P* \< 0.001; women: 93.1%, *P* \< 0.001). According to sensitivity analyses, DM was associated with an increased risk of gastric cancer mortality in men when excluding the Tseng study, the study specific reported SMR at different age stages, and the effect estimate was inconceivable higher in DM patients aged 25-64 years \[[@R52]\] (RR: 1.17; 95%CI: 1.07-1.28; *P* \< 0.001; I-square: 1.2%; *P* value for heterogeneity: 0.400; Supplemental 2: [Table S3](#SD1){ref-type="supplementary-material"}), which specifically included a wide range of participants and had a mean age greater than 25.0 years. Similarly, after excluding the Tseng study \[[@R52]\], we noted participants with DM may have an increased risk of gastric cancer mortality in women (RR: 1.21; 95%CI: 1.06-1.40; *P* = 0.006; I-square: 0.0%; *P* value for heterogeneity: 0.533; Supplemental 2: [Table S4](#SD1){ref-type="supplementary-material"}).

![Association of diabetes mellitus with the risk of gastric cancer mortality in men (**A**) and women (**B**).](oncotarget-08-44881-g004){#F4}

Subgroup analysis {#s2_6}
-----------------

Substantial heterogeneity was detected for gastric cancer incidence and mortality in men and women. We therefore performed subgroup analyses to minimize heterogeneity and evaluate the potential role of DM on the progression of gastric cancer among the included studies. First, DM was associated with an increased risk of gastric cancer incidence in men if the study used SIR/SMR as an effect estimate index (Table [2](#T2){ref-type="table"}). Second, participants with DM showed an increased risk of gastric cancer mortality if the study was conducted on women in Western countries, the study used OR, RR, or HR as an effect estimate index, and the study was not adjusted for smoking or alcohol consumption (Table [3](#T3){ref-type="table"}). Third, DM significantly increased the risk of gastric cancer mortality in men if the mean age was less than 55 years, the study used OR, RR, or HR as an effect estimate index, and the study was not adjusted for alcohol consumption (Table [3](#T3){ref-type="table"}). There were no gender differences for gastric cancer incidence and gastric cancer mortality in specific subsets.

###### Subgroup analysis of relative risk (ratios) for gastric cancer in men and women

  Subgroup                     Stratified analyses   Sex                RR and 95%CI       *P* value         I-square and *P* value for heterogeneity   RRR and 95%CI      *P* value for interaction test
  ---------------------------- --------------------- ------------------ ------------------ ----------------- ------------------------------------------ ------------------ --------------------------------
  Country                      Western countries     Men                0.98 (0.84-1.15)   0.817             73.3% (0.005)                              0.92 (0.75-1.14)   0.466
  Women                        1.06 (0.92-1.22)      0.400              0.0% (0.456)                                                                                       
  Eastern countries            Men                   1.02 (0.86-1.20)   0.817              46.3% (0.097)     0.97 (0.72-1.32)                           0.851              
  Women                        1.05 (0.82-1.36)      0.690              55.0% (0.049)                                                                                      
  Age at baseline              ≥55                   Men                1.06 (0.90-1.25)   0.481             64.4% (0.015)                              0.95 (0.77-1.19)   0.679
  Women                        1.11 (0.96-1.28)      0.175              0.0% (0.922)                                                                                       
  \<55                         Men                   1.06 (0.93-1.22)   0.373              26.5% (0.257)     0.91 (0.67-1.24)                           0.566              
  Women                        1.16 (0.88-1.53)      0.306              59.0 (0.087)                                                                                       
  Effect estimate              SIR/SMR               Men                1.20 (1.05-1.36)   0.007             0.0% (0.666)                               1.09 (0.88-1.35)   0.420
  Women                        1.10 (0.93-1.30)      0.264              0.0% (0.933)                                                                                       
  OR, RR, or HR                Men                   0.97 (0.87-1.09)   0.598              66.5% (0.002)     0.92 (0.74-1.16)                           0.487              
  Women                        1.05 (0.87-1.28)      0.594              49.4% (0.054)                                                                                      
  Follow-up duration (yr)      ≥15                   Men                0.99 (0.61-1.61)   0.957             73.2% (0.053)                              1.65 (0.38-7.21)   0.506
  Women                        0.60 (0.15-2.43)      0.477              82.7% (0.016)                                                                                      
  \<15                         Men                   0.98 (0.88-1.10)   0.756              64.0 (0.005)      0.91 (0.76-1.08)                           0.273              
  Women                        1.08 (0.95-1.24)      0.248              13.2% (0.327)                                                                                      
  Adjusted BMI                 Yes                   Men                0.98 (0.83-1.16)   0.826             42.5% (0.138)                              1.02 (0.58-1.79)   0.942
  Women                        0.96 (0.56-1.63)      0.870              70.3% (0.018)                                                                                      
  No                           Men                   1.01 (0.87-1.18)   0.889              68.5% (0.007)     0.92 (0.77-1.10)                           0.359              
  Women                        1.10 (0.99-1.21)      0.067              0.0% (0.660)                                                                                       
  Adjusted smoking             Yes                   Men                1.03 (0.90-1.18)   0.690             27.0 (0.241)                               0.93 (0.66-1.30)   0.666
  Women                        1.11 (0.81-1.51)      0.509              65.4% (0.021)                                                                                      
  No                           Men                   1.00 (0.85-1.18)   0.995              74.5% (0.001)     0.96 (0.78-1.19)                           0.713              
  Women                        1.04 (0.91-1.18)      0.592              0.0% (0.816)                                                                                       
  Adjusted alcohol drinking    Yes                   Men                1.00 (0.89-1.12)   0.952             61.5% (0.024)                              0.90 (0.65-1.26)   0.538
  Women                        1.11 (0.81-1.51)      0.509              65.4% (0.021)                                                                                      
  No                           Men                   1.02 (0.78-1.33)   0.879              76.5% (0.002)     0.98 (0.73-1.32)                           0.898              
  Women                        1.04 (0.91-1.18)      0.592              0.0% (0.816)                                                                                       
  Adjusted physical activity   Yes                   Men                0.98 (0.80-1.19)   0.802             0.0% (0.498)                               0.77 (0.48-1.25)   0.291
  Women                        1.27 (0.82-1.97)      0.284              63.0% (0.067)                                                                                      
  No                           Men                   1.01 (0.89-1.14)   0.913              75.6% (\<0.001)   0.97 (0.81-1.17)                           0.757              
  Women                        1.04 (0.91-1.20)      0.556              27.8% (0.216)                                                                                      

###### Subgroup analysis of relative risk (ratios) for gastric cancer mortality in men and women

  Subgroup                     Stratified analyses    Sex                    RR and 95%CI           *P* value             I-square and *P* value for heterogeneity   RRR and 95%CI      *P* value for interaction test
  ---------------------------- ---------------------- ---------------------- ---------------------- --------------------- ------------------------------------------ ------------------ --------------------------------
  Country                      Western countries      Men                    1.19 (0.99-1.43)       0.070                 24.5% (0.264)                              0.91 (0.70-1.18)   0.467
  Women                        **1.31 (1.09-1.57)**   **0.004**              **0.0% (0.739)**                                                                                           
  Eastern countries            Men                    1.61 (0.85-3.03)       0.144                  99.0% (\<0.001)       1.01 (0.38-2.66)                           0.980              
  Women                        1.59 (0.77-3.31)       0.212                  97.4% (\<0.001)                                                                                            
  Age at baseline              ≥55                    Men                    1.04 (0.84-1.28)       0.737                 0.0% (0.503)                               0.85 (0.61-1.20)   0.359
  Women                        1.22 (0.93-1.59)       0.151                  0.0% (0.773)                                                                                               
  \<55                         Men                    **1.16 (1.05-1.29)**   **0.004**              **0.0% (0.834)**      1.06 (0.84-1.35)                           0.612              
  Women                        1.09 (0.88-1.36)       0.438                  \-                                                                                                         
  Effect estimate              SIR/SMR                Men                    1.65 (0.88-3.11)       0.120                 90.2% (0.001)                              0.98 (0.39-2.46)   0.959
  Women                        1.69 (0.86-3.32)       0.127                  87.9% (0.004)                                                                                              
  OR, RR, or HR                Men                    **1.17 (1.04-1.33)**   **0.012**              **25.9% (0.257)**     0.96 (0.79-1.17)                           0.674              
  Women                        **1.22 (1.05-1.42)**   **0.009**              **6.4% (0.343)**                                                                                           
  Follow-up duration (yr)      ≥15                    Men                    1.24 (0.67-2.29)       0.493                 \-                                         \-                 \-
  Women                        \-                     \-                     \-                                                                                                         
  \<15                         Men                    1.34 (0.92-1.96)       0.129                  96.7% (\<0.001)       0.96 (0.56-1.64)                           0.874              
  Women                        1.40 (0.95-2.06)       0.085                  97.1% (\<0.001)                                                                                            
  Adjusted BMI                 Yes                    Men                    1.04 (0.84-1.28)       0.737                 0.0% (0.503)                               0.85 (0.61-1.20)   0.359
  Women                        1.22 (0.93-1.59)       0.151                  0.0% (0.773)                                                                                               
  No                           Men                    1.48 (0.96-2.28)       0.075                  97.1% (\<0.001)       0.97 (0.50-1.88)                           0.922              
  Women                        1.53 (0.92-2.53)       0.100                  95.7% (\<0.001)                                                                                            
  Adjusted smoking             Yes                    Men                    **1.14 (1.03-1.25)**   **0.008**             **0.0% (0.498)**                           1.00 (0.82-1.23)   1.00
  Women                        1.14 (0.95-1.36)       0.165                  0.0% (0.494)                                                                                               
  No                           Men                    **1.58 (1.04-2.39)**   **0.032**              **91.1% (\<0.001)**   0.99 (0.54-1.82)                           0.968              
  Women                        **1.60 (1.02-2.50)**   **0.039**              **90.5% (\<0.001)**                                                                                        
  Adjusted alcohol drinking    Yes                    Men                    1.12 (0.98-1.27)       0.095                 23.9% (0.252)                              0.98 (0.79-1.23)   0.875
  Women                        1.14 (0.95-1.36)       0.165                  0.0% (0.494)                                                                                               
  No                           Men                    **1.51 (1.04-2.21)**   **0.031**              **88.1% (\<0.001)**   0.94 (0.53-1.70)                           0.846              
  Women                        **1.60 (1.02-2.50)**   **0.039**              **90.5% (\<0.001)**                                                                                        
  Adjusted physical activity   Yes                    Men                    1.02 (0.81-1.29)       0.853                 0.0% (0.506)                               0.82 (0.55-1.22)   0.320
  Women                        1.25 (0.90-1.73)       0.181                  \-                                                                                                         
  No                           Men                    1.45 (0.95-2.20)       0.085                  97.1% (\<0.001)       1.01 (0.55-1.86)                           0.982              
  Women                        1.44 (0.92-2.24)       0.108                  94.2% (\<0.001)                                                                                            

Publication bias {#s2_7}
----------------

Review of the funnel plots could not rule out the potential for publication bias for gastric cancer incidence and gastric cancer mortality (Figure [5](#F5){ref-type="fig"}). The Egger \[[@R47]\] and Begg tests \[[@R48]\] results showed no evidence of publication bias for gastric cancer incidence (*P* value for Egger: 0.892; *P* value for Begg: 0.621) or gastric cancer mortality (*P* value for Egger: 0.148; *P* value for Begg: 0.348).

![Funnel plots for gastric cancer incidence (**A**) and gastric cancer mortality (B).](oncotarget-08-44881-g005){#F5}

DISCUSSION {#s3}
==========

Our current study was based on cohort studies and explored all possible correlations between DM and the outcomes of gastric cancer incidence and gastric cancer mortality. This large quantitative study included 8,559,861 participants from 22 cohort studies with a broad range of populations. The findings from our study indicate that DM has no overall significant impact on the risk of gastric cancer incidence and gastric cancer mortality. Subgroup analyses suggested mean age at baseline, effect estimate, adjusted smoking, alcohol drinking or not might affect the incidence of gastric cancer mortality in men, and Country, effect estimate, adjusted smoking, alcohol drinking or not were affect gastric cancer mortality in women. However, there were no gender differences between men and women for any correlations of DM and gastric cancer.

The methodological evaluation of each included study was limited by the representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of DM, demonstration that outcomes were not present at the start of study, comparability on the basis of the design or analysis, assessment of outcome, adequate follow-up duration, and adequate follow-up rate. Our meta-analysis of cohort studies provides unclear results for the selection of the non-exposed cohort if the study reported SIR/SMR as the effect estimate, which contributed to heterogeneity in overall analysis. Therefore, the summary results might be biased due to different effect estimate indexes.

A previous meta-analysis suggested that DM patients had a similar risk of gastric cancer incidence and substantial heterogeneity was observed. Furthermore, subgroup analyses indicated DM significantly increased the risk of gastric cancer in men, whereas it had no effect in women \[[@R23]\]. However, another meta-analysis suggested that total participants with DM have an increased risk of gastric cancer, and are positively associated with gastric cancer mortality \[[@R22]\]. The inherent limitation of those previous meta-analyses is that case control studies were included and various confounding factors might be biasing the results, as several important confounders cannot be adjusted. We therefore conducted this study to evaluate the relationship between DM and the risk of gastric cancer incidence or mortality on the basis of gender.

Most of our findings were in agreement with a recently published large cohort study conducted in the UK \[[@R54]\]. This prospective study included 28,900 patients with insulin-treated diabetes and found that DM was not associated with gastric cancer incidence or mortality risk. The reason for this could be that the study design used total cancer events as primary outcomes, and the sample size might not have been sufficient to evaluate the relationship between DM and gastric cancer risk. Event rates were lower than expected, which always requires broad confidence intervals, resulting in no statistically significant difference. Chodick et al \[[@R51]\] conducted a cohort study and, after an 8 year follow-up, concluded that there was no significant increase in overall risk of gastric cancer incidence between DM and non-DM participants. Xu et al \[[@R63]\] did not find any evidence that type 2 DM was associated with an increased risk of gastric cancer either in men or in women. Our current study also indicated that DM has no significant effect on the overall risk of gastric cancer. Yet symptoms of gastric cancer can be hidden and diagnosis might come late in DM patients with gastric cancer, which could incorrectly lend toward this conclusion of non-significant correlations.

There was no significant difference between DM and non-DM participants and the risk of gastric cancer incidence or mortality. However, several studies included in our study reported inconsistent results. Jee et al \[[@R16]\] indicated that elevated fasting serum glucose and DM are independent risk factors for gastric cancer, and the relative risk tends to increase accompanying an increased fasting serum glucose level. Similarly, Lin et al \[[@R18]\] found a significant association between DM and the higher risk of gastric cancer. They explained this relationship saying that DM patients with hyperglycemia may cause dysregulation of energy balance, which could affect intracellular metabolism and impair immune system and might play an important role in the progression of gastric cancer \[[@R64]\]. Conversely, a significantly reduced risk for gastric cancer following DM was detected in Khan et al and Adami et al \[[@R20], [@R21]\]. These could be due to time effects in certain cases, with an early decrease followed by an increased risk.

Subgroup analysis suggested that males with DM were associated with an increased risk of gastric cancer if the study used SIR/SMR as an effect estimate index. Furthermore, participants with DM might have an increased risk of gastric cancer mortality in multiple subsets. It is possible that longer diabetes duration could be associated with insulin resistance and hyperinsulinemia, which might has an effect on promoting cell growth and proliferation. Although an important population-based study compared the incidence of gastric cancer in insulin users and nonusers and showed a lack of association between insulin use and gastric cancer, which might due to DM patients received insulin or not with different DM status \[[@R65]\]. Furthermore, most confounders cannot be adjusted in several studies, which might bias the summary result. Finally, several conclusions may be variable since smaller cohorts were included. Therefore, relative results with a comprehensive review were provided in our study.

We noted higher heterogeneity for the summary results, the reason for this could be the baseline characteristics might affect the relationship between DM and gastric cancer incidence or mortality. Tseng et al indicated hyperglycemia, Helicobacter pylori (HP) infection, high salt intake, medications and comorbidities might play an important role on the risk of gastric cancer. They stated DM patients was associated with higher infection rate, lower eradication rate and higher reinfection rate of HP. Further, salt intake might affect HP infection \[[@R66]\]. However, salt intake and HP infection status were not reported in the studies included in our meta-analysis. In addition, patients in different ethnicities and geographical regions with different levels of salt intake and HP infection, which may affect the relationship between DM and gastric cancer and contribute to the potential heterogeneity. Furthermore, Tseng et al resulted DM patients received metformin might affect the incidence of gastric cancer \[[@R67]\]. Finally, they indicated DM was contributed a harmful effect on gastric cancer, whereas insulin use has no significant effect on the gastric cancer risk \[[@R65]\]. In this study, mostly studies included could not adjusted antidiabetic drugs, which may introduce potential heterogeneity.

Three strengths of our study should be highlighted. First, only cohort studies were included, which should eliminate uncontrolled biases. Second, the large sample size allowed us to quantitatively assess the association of DM with the risk of gastric cancer and mortality, potentially making our findings more robust than those of any individual study. Third, the summary RRR was employed to evaluate gender differences for this relationship.

The limitations of our study are as follows: (1) the adjusted models are different across the included studies, and these factors might play an important role in the development of gastric cancer; (2) the incidence of gastric cancer and mortality was difference, which might introduce uncontrol biases; (3) postmenopausal status in women might affect the incidence of gastric cancer or mortality, whereas the results of stratified analysis in individual study was not available; (4) in a meta-analysis of published studies, publication bias is an inevitable problem; and (5) the analysis used pooled data (individual data were not available), which restricted us from performing a more detailed relevant analysis and obtaining more comprehensive results.

The findings of this study suggest that DM is not associated with overall changes in gastric cancer or mortality risk. Furthermore, subgroup analyses suggested that certain participants (mean age at baseline less than 55.0, used RR or HR as effect estimate, the study adjusted smoking or not, and the study not adjusted alcohol drinking in men, and the study conducted in Western Countries, used RR or HR as effect estimate, not adjusted smoking or alcohol drinking in women.) with DM may see a higher risk of gastric cancer mortality. Future studies are needed to focus on specific populations and evaluate potential interactions of other important confounders.

MATERIALS AND METHODS {#s4}
=====================

We followed Preferred Reporting Items for Systematic reviews and Meta-analysis guideline in reporting this systematic review and meta-analysis \[[@R38]\].

Data Sources, Search Strategy, and Selection Criteria {#s4_1}
-----------------------------------------------------

Literature research was carried out by searching relevant publications via the electronic databases PubMed, EmBase and the Cochrane Library. Any cohort study that examined the relationship between DM and the risk of gastric cancer incidence or mortality was eligible for inclusion in our study, and no restrictions were placed on language or publication status (published, in press, or in progress). The following search terms ("gastric" OR "stomach") AND ("carcinoma" OR "cancer" OR "neoplasm" OR "adenocarcinoma") AND ("diabetes" OR "diabetes mellitus") were searched (from inception to June 2016). The details of the search strategy are listed in Supplemental 1. Manual searches of the reference lists from all the relevant studies and review articles were conducted as well. The medical subject heading, methods, population status, design, exposure, and outcome variables of these articles were used to identify the relevant studies.

The literature search was independently undertaken by 2 authors using a standardized approach. Any inconsistencies between these 2 authors were settled by the primary author until a consensus was reached. The criteria for eligibility of the studies were as follows: (1) the study had to have a cohort design (prospective or retrospective); (2) the study investigated the association between DM and the risk of gastric cancer incidence or mortality; and (3) the study should report effect estimates (risk ratio \[RR\], hazard ratio \[HR\], standard incidence/mortality ratio \[SIR/SMR\]) and 95% confidence intervals (CIs) for comparisons of participants with DM and those without DM. We used the following exclusion criteria: (1) the type of study was non-cohort design; (2) the studies evaluated other factors such that the relationship between DM and gastric cancer was not available; and (3) the publications were duplicated studies, abstracts, reviews, or the reported data from an abstract or from a meeting.

Data collection and quality assessment {#s4_2}
--------------------------------------

Studies were reviewed and data extracted independently by two authors using a pre-designed standard form. The following data were extracted from each study: the study group or first author\'s name, publication year, country, assessment of exposure, sample size, age at baseline, gender, percentage of participants overweight, gastric cancer cases, gastric cancer mortality cases, effect estimate, follow-up duration, and adjusted factors. For studies that reported several multivariable adjusted RRs, we selected the effect estimate that was maximally adjusted for potential confounders. Attempts were made to contact the authors for missing data.

The Newcastle-Ottawa Scale (NOS), which is quite comprehensive and has been partially validated for evaluating the quality of observational studies in meta-analysis, was used to evaluate methodological quality \[[@R39]\]. The NOS is based on the following 3 subscales: selection (4 items), comparability (1 item), and outcome (3 items). A "star system" (range, 0-9) has been developed for assessment (Table [1](#T1){ref-type="table"}). The data extraction and quality assessment were conducted independently by 2 authors. Information was examined and adjudicated independently by an additional author referring to the original studies.

Statistical analysis {#s4_3}
--------------------

We examined the relationship between DM and risk of gastric cancer incidence or mortality on the basis of the effect estimate (RR, HR, SIR/SMR) and its 95% CI published in each study. If more than one, subsets were pooled by using a fixed effect model to calculate their RRs and 95%CIs for effect estimates of each study \[[@R40]\]. We used the random-effects model to calculate summary RRs and 95%CIs for participants with DM versus participants without DM \[[@R41]\]. We probed the association between DM and gastric cancer in men and women separately. Finally, the ratios of relative risk (RRRs) and the corresponding 95%CIs were used to calculate gender difference for the relationship between DM and gastric cancer incidence or mortality \[[@R42]\].

Heterogeneity between studies was investigated by using I-square and Q statistic, and were regarded as significant heterogeneity if the *P* value was less than 0.10 \[[@R43], [@R44]\]. Sensitivity analyses were also conducted to evaluate the impact of individual studies by systematically removing each individual study from the meta-analysis \[[@R45]\]. Subgroup analyses were conducted for gastric cancer incidence and mortality in men and women on the basis of country, age at baseline, effect estimate, follow-up duration, adjusted BMI, smoking, alcohol consumption, and physical activity or lack thereof. Interaction tests for differences between men and women in subsets were also calculated \[[@R46]\]. Several methods were employed to check for potential publication bias, including visual inspections of funnel plots for gastric cancer incidence and gastric cancer mortality and the Egger \[[@R47]\] and Begg \[[@R48]\] tests. All reported *P* values are 2-sided, and *P* values less than 0.05 were regarded as statistically significant. Statistical analyses were performed using STATA software (version 12.0; Stata Corporation, College Station, TX, USA).
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==============================

This work was supported by the National Natural Science Foundation of China (No. 81272718, 81302125 and 81372550). The sponsors played no role in the study design, data collection, or analysis, or decision to submit the article for publication.

**CONFLICTS OF INTEREST**

No potential conflicts of interest were disclosed.
